# New clinical trials in Dominican Republic: 21 since Nov 2024

Updated November 4, 2026.

21 clinical studies with a site in Dominican Republic were first posted on ClinicalTrials.gov from December 18, 2024 to November 4, 2026; 16 have an industry sponsor and 11 are recruiting or about to. The newest, NCT07917507, was posted on November 4, 2026: A Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and... (Colgate Palmolive).

## The full list

New clinical trials with a site in Dominican Republic: 21 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/dominican-republic

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 21
- Industry sponsored: 16
- Recruiting or not yet: 11
- Latest posted: November 4, 2026

## Newest trials

The newest 21 of 21, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07917507 | A Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis | Colgate Palmolive | Phase 3 | Active not recruiting | Plaque, Gingivitis | 84 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917507) |
| October 21, 2026 | NCT07886268 | A Study to Evaluate the Efficacy and Safety of TP-06 for PCED | Tarsus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Persistent Corneal Epithelial Defect | 32 | Dominican Republic, El Salvador, Mexico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886268) |
| October 5, 2026 | NCT07856745 | Efficacy and Safety of FLEXIPORT Implantable Port in Chemotherapeutic Treatments | Portal Access Ltd. | Not applicable | Completed | Neoplasms | 40 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856745) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | Argentina, Dominican Republic, Mexico, Panama, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 25, 2026 | NCT07786025 | DisTal Arterio-Venous Fistula Feasibility | Distal Inc. | Not applicable | Active not recruiting | End-Stage Renal Disease Requiring Haemodialysis | 100 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786025) |
| August 3, 2026 | NCT07742306 | Continuous Glucose Monitoring in High-Risk Children and Youth With Type 1 Diabetes in the Dominican Republic | Life for a Child Program, Diabetes Australia | Observational | Recruiting | Type 1 Diabetes (T1D) | 40 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742306) |
| December 19, 2025 | NCT07294573 | Maternal Health Assessment in Pediatric Care | John James Parker | Not applicable | Active not recruiting | Postpartum Care, Primary Care, Mental Health, Family Planning, Care Coordination | 150 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294573) |
| December 11, 2025 | NCT07276672 | Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the... | Colgate Palmolive | Phase 3 | Completed | Whitening | 80 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276672) |
| December 4, 2025 | NCT07264205 | RT-310 Safety and Feasibility BPH Study | Resurge Therapeutics Inc. | Phase 1/2 | Active not recruiting | BPH (Benign Prostatic Hyperplasia) | 20 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264205) |
| December 3, 2025 | NCT07262320 | Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America | University of Alabama at Birmingham | Observational | Recruiting | Dialysis, Critically Ill Acute Kidney Injury, Renal Replacement Therapy for Acute Kidney Injury in ICU, Acute Kidney... | 1,000 | Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262320) |
| November 25, 2025 | NCT07247188 | Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sanofi | Phase 3 | Recruiting | Sickle Cell Disease | 100 | Dominican Republic, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247188) |
| November 6, 2025 | NCT07225530 | Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) | Columbia University | Not applicable | Recruiting | HIV Infections, HPV Infection, Cervical Cancer | 600 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225530) |
| August 29, 2025 | NCT07147192 | Feasibility Study of an Accommodating IOL Design | Alcon Research | Not applicable | Terminated | Aphakia | 17 | Costa Rica, Dominican Republic, El Salvador, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07147192) |
| August 22, 2025 | NCT07137767 | Quantitative Refractive Crosslinking in Presbyopia Aged Patients | TECLens, Inc. | Not applicable | Not yet recruiting | Presbyopia | 25 | Brazil, Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07137767) |
| August 12, 2025 | NCT07116772 | Serial Assessment of Fertility Experiences | Children's Hospital Medical Center, Cincinnati | Observational | Recruiting | Sickle Cell Anemia | 250 | Dominican Republic, Jamaica, Tanzania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116772) |
| June 29, 2025 | NCT07044297 | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | 4,390 | Argentina, Brazil, Chile, Colombia, Dominican Republic, France, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044297) |
| June 11, 2025 | NCT07016607 | Vital Peripheral Intravenous Catheter Feasibility | Embrace Medical Ltd. | Not applicable | Completed | Catheterization, Peripheral Venous | 100 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07016607) |
| May 31, 2025 | NCT06998056 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis (Eczema) | 101 | Canada, Dominican Republic, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998056) |
| February 11, 2025 | NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately... | Hoffmann-La Roche | Phase 3 | Recruiting | Moderately to Severely Active Crohns Disease | 600 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819878) |
| February 3, 2025 | NCT06806137 | A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3... | GlaxoSmithKline | Phase 3 | Recruiting | Chickenpox | 600 | Dominican Republic, Honduras | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06806137) |
| December 18, 2024 | NCT06740630 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | GlaxoSmithKline | Phase 3 | Recruiting | Chickenpox | 1,840 | Belgium, Colombia, Czechia, Dominican Republic, Estonia, Mexico, Poland, Puerto... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06740630) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Colgate Palmolive | 2 | November 4, 2026 |
| GlaxoSmithKline | 2 | February 3, 2025 |
| Tarsus Pharmaceuticals, Inc. | 1 | October 21, 2026 |
| Portal Access Ltd. | 1 | October 5, 2026 |
| ModernaTX, Inc. | 1 | September 9, 2026 |
| Distal Inc. | 1 | August 25, 2026 |
| Life for a Child Program, Diabetes Australia | 1 | August 3, 2026 |
| John James Parker | 1 | December 19, 2025 |
| Resurge Therapeutics Inc. | 1 | December 4, 2025 |
| University of Alabama at Birmingham | 1 | December 3, 2025 |
| Sanofi | 1 | November 25, 2025 |
| Columbia University | 1 | November 6, 2025 |
| Alcon Research | 1 | August 29, 2025 |
| TECLens, Inc. | 1 | August 22, 2025 |
| Children's Hospital Medical Center, Cincinnati | 1 | August 12, 2025 |
| Merck Sharp & Dohme LLC | 1 | June 29, 2025 |
| Embrace Medical Ltd. | 1 | June 11, 2025 |
| Arcutis Biotherapeutics, Inc. | 1 | May 31, 2025 |
| Hoffmann-La Roche | 1 | February 11, 2025 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Anemia, Sickle Cell](https://specstream.ai/data/clinical-trials/condition/anemia-sickle-cell) | 2 | November 25, 2025 |
| Chickenpox | 2 | February 3, 2025 |
| Plaque, Amyloid | 1 | November 4, 2026 |
| [Gingivitis](https://specstream.ai/data/clinical-trials/condition/gingivitis) | 1 | November 4, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 1 | October 5, 2026 |
| Coronavirus Infections | 1 | September 9, 2026 |
| Virus Diseases | 1 | September 9, 2026 |
| [COVID-19](https://specstream.ai/data/clinical-trials/condition/covid-19) | 1 | September 9, 2026 |
| Fistula | 1 | August 25, 2026 |
| [Diabetes Mellitus, Type 1](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-1) | 1 | August 3, 2026 |
| [Psychological Well-Being](https://specstream.ai/data/clinical-trials/condition/psychological-well-being) | 1 | December 19, 2025 |
| [Prostatic Hyperplasia](https://specstream.ai/data/clinical-trials/condition/prostatic-hyperplasia) | 1 | December 4, 2025 |
| [Acute Kidney Injury](https://specstream.ai/data/clinical-trials/condition/acute-kidney-injury) | 1 | December 3, 2025 |
| [HIV Infections](https://specstream.ai/data/clinical-trials/condition/hiv-infections) | 1 | November 6, 2025 |
| Papillomavirus Infections | 1 | November 6, 2025 |
| [Uterine Cervical Neoplasms](https://specstream.ai/data/clinical-trials/condition/uterine-cervical-neoplasms) | 1 | November 6, 2025 |
| Aphakia | 1 | August 29, 2025 |
| [Cataract](https://specstream.ai/data/clinical-trials/condition/cataract) | 1 | August 29, 2025 |
| Presbyopia | 1 | August 22, 2025 |
| [Myopia](https://specstream.ai/data/clinical-trials/condition/myopia) | 1 | August 22, 2025 |
| Hyperopia | 1 | August 22, 2025 |
| [Acquired Immunodeficiency Syndrome](https://specstream.ai/data/clinical-trials/condition/acquired-immunodeficiency-syndrome) | 1 | June 29, 2025 |
| [Dermatitis, Atopic](https://specstream.ai/data/clinical-trials/condition/dermatitis-atopic) | 1 | May 31, 2025 |
| Eczema | 1 | May 31, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 7 | November 4, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 7 | October 5, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 3 | October 21, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 3 | August 3, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 1 | December 4, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).